Glycomimetics Inc (GLYC): Helen M. Thackray , VP Clinical Development, CMO of Glycomimetics Inc sold 22,000 shares on Jul 1, 2016. The Insider selling transaction was reported by the company on Jul 6, 2016 to the Securities and Exchange Commission. The shares were sold at $7.03 per share for a total value of $153,953.84 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 7, 2016, Mark Alan Goldberg (director) purchased 10,397 shares at $4.77 per share price.On Nov 18, 2015, Peter J Barris (10% owner) sold 452 shares at $6.91 per share price.Also, On Nov 18, 2015, Scott D Sandell (10% owner) sold 452 shares at $6.91 per share price.On Nov 18, 2015, M James Barrett (director 10% owner) sold 452 shares at $6.91 per share price.
Shares of GlycoMimetics Inc (GLYC) ended Tuesday, Jul 6, 2016 session in red amid volatile trading. The shares closed down -0.67 points or -8.92% at $6.84 with 62,790 shares getting traded. Post opening the session at $7.57, the shares hit an intraday low of $6.67 and an intraday high of $7.57 and the price vacillated in this range throughout the day. The company has a market cap of $132 M and the number of outstanding shares has been calculated to be 1,93,50,322 shares. The 52-week high of GlycoMimetics Inc is $9.25 and the 52-week low is $3.7.
GlycoMimetics Inc. (GlycoMimetics) is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs to address medical needs. The Company’s pipeline includes GMI-1070 (Rivipansel) GMI-1271 GMI-1359 (E-selectin and CXCR4 antagonist) GMI-1051 and Galectin inhibitors. The Company developing rivipansel to treat VOC (vaso-occlusive crisis) with the goal of reducing duration of VOC episodes length of hospital stay and use of opioid analgesics for pain management. The Company is developing GMI-1271 a specific E-selectin antagonist to be used in combination with chemotherapy to treat AML (acute myeloid leukemia) and other hematologic cancers. GMI-1359 simultaneously inhibits both E-selectin and CXCR4 for use in the treatment of cancers with bone marrow involvement such as myeloma. GMI-1051 is an antagonist of two pseudomonas virulence factors PA-IL and PA-IIL.